Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Dow Bags Gain on Value Stocks; FDA Approves Gilead's Anti-Viral Drug

Published 10/22/2020, 03:57 PM
Updated 10/22/2020, 04:08 PM
© Reuters.

© Reuters.

By Yasin Ebrahim

Investing.com – The Dow closed higher Thursday, as value stocks plugged the gap left by a fall in tech stocks on signs of progress on stimulus after House Speaker Nancy Pelosi suggested a deal was close.

Gilead Sciences Inc (NASDAQ:GILD) jumped 4% in after-hours trading after the FDA approved its anti-viral drug.

The Dow Jones Industrial Average rose 0.55%, or 154 points. The S&P 500 was up 0.55%, while the Nasdaq Composite added 0.57%.

Pelosi said a deal on stimulus “just about there," though added that key issues including state and local funding as well as liability protection were yet to be resolved.

Still, as any eventual stimulus proposal would need backing from congress, there is likely to be further stumbling blocks ahead. Senate GOP leader Mitch McConnell has expressed concerns over the size of the deal on the table, believed to be around $1.9 trillion, still below the Democrats' $2.2 trillion proposal, preferring instead to roll out targeted relief measures.  

In another boost to sentiment on the economy, jobless claims fell below 800,000 for the first since the pandemic struck in mid-March.

The Labor Department said 787,000 people filed for unemployment insurance, down 55,000 from the prior week's downwardly revised 842,000, and well above economists' forecast for 870,000.

Some economists, however, questioned whether the trend will continue in the wake of rising Covid-19 cases.

"[W]e doubt it will continue as Covid infections spread rapidly, pushing down demand for discretionary consumer services, especially in the hospitality sector," Pantheon Macroeconomics said in a note.

The renewed hopes for the economic recovery to continue, however, triggered a climb in value stocks with financials and energy in the ascendency.

Energy jumped 4% as oil prices clawed back some of their losses from a day earlier, when a jump in gasoline supplies intensified fears of demand weakening.

Financials, meanwhile, were pushed higher by a sharp uptick in banking stocks as the favorable backdrop of rising Treasury yields continued.

Wells Fargo (NYSE:WFC) added 2%, while Bank of America (NYSE:BAC) and JPMorgan Chase (NYSE:JPM) climbed more than 3%.

The earnings parade gathered pace as mega blue chips reported quarterly performance.

Tesla Inc (NASDAQ:TSLA) eased from session highs to end nearly 1% after the electric automaker said it was on track to for 500,000 deliveries this year, and reported quarterly results that beat on both the top and bottom lines.

Coca-Cola Company (NYSE:KO) added 1% after its better-than-expected quarterly results suggested the worst of the hit from pandemic was in the rearview mirror as sales fell 6% in the quarter, a marked improvement from the 26% slump in the second quarter.

Airlines, among the hardest hit sectors from the pandemic, reporting mixed results as American Airlines (NASDAQ:AAL) reported narrower-than-expected results, while Alaska Air Group Inc (NYSE:ALK) revealed deeper losses, though said it had cut its cash burn.

Tech was among the biggest decliners on the day as the fab 5 traded slipped. Apple (NASDAQ:AAPL), Amazon.com (NASDAQ:AMZN), Facebook (NASDAQ:FB) were below the flatline, while Microsoft (NASDAQ:MSFT) finished flat and Google-parent Alphabet (NASDAQ:GOOGL) rose 1%.

On the vaccine front, The Federal Food and Drug Administration approved Gilead (NASDAQ:GILD)'s remdesivir to treat patients with COVID-19 requiring hospitalization. "The drug is now widely available in hospitals across the country, following early investments to rapidly expand manufacturing capacity to increase supply," the company said.

Latest comments

How much this drug manufacturer funded coming from USA presidential election?
no one wants remdesivir
Remdesivir efficiency has been verified by comprehensive FDA study. The latter is the only authority to approve new medicines in this country. On the other hand, “WHO study” is a purely fictional thing, invented and promoted by media to serve obvious political purposes.
Remdisivir was found to in ineffective at saving any lives by a huge WHO study--71,000 cases. This is pure politics and the SEC should look at this. Enough.
there is no value in this bubble market
Thanks president Trump, job well done fighting the virus!
GILD presents good investment opportunity, esp. now with share price artificially depressed, mostly by political reasons.
Artificially depressed... are you serious?
 Certainly, I am serious. Btw, many stocks are depressed on pumped up on market. Did not you know this?
https://time.com/5901087/remdesivir-conflicting-studies/
it doesn't work !
News for 1 month for markets up
I have heard that according to WHO this drug ( remdesivir )  doesn't work at all ?
what a ridiculous comment. Tell your brain cell to wake the other one up. It needs help.
https://www.rxlist.com/consumer_remdesivir_rdv/drugs-condition.htm
well said
APPROVED!
Convenient for the compromised FDA to make this decision thw day Gilead hits a 52-week low. Definitely nothing sketchy going on here. /s
Where’s the lie though?
hi
cnn say dow up for stimulis , investing say for vaccine, lol funny with fake news , go down
both
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.